What is Hunter Syndrome?

  • Hunter syndrome, also known as mucopolysaccharidosis type II, or MPS 2, is a rare, hereditary metabolic disorder that primarily affects males; it is often severe and almost always progressive.
  • In people with MPS syndrome, the  iduronate-2-sulfatase (IDS) enzyme, which  breaks down complex sugars, is missing or not working properly.
  • This leads to an abnormal buildup of complex sugars in tissues throughout the body, including the brain, skeleton, joints, spinal cord, heart spleen, or liver.
  • Physical symptoms include growth delay, joint stiffness and coarsening of facial features
  • When severe, MPS disease can cause respiratory and cardiac problems, enlargement of the liver and spleen, and premature death.
  • Hunter syndrome can also cause neurological deficits that can lead to progressive dementia and a progressive decrease in IQ points.
  • TO QUALIFY,
    YOU MUST BE:

    • Ages 18 or older.
    • ​Diagnosed with Hunter Syndrome.
    • Available for 8 weeks of investigational treatment.
    • Willing to discontinue standard enzyme replacement therapy and switch to AGT-182 for the duration of their participation in the clinical trial.
  • Inquire about the
    clinical trial: